Literature DB >> 12270701

Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease.

David Blum1, Marie-Christine Galas, David Gall, Laetitia Cuvelier, Serge N Schiffmann.   

Abstract

In the present study, we aimed to determine the time-course of neurochemical changes occurring following metabolic impairments produced by 3-nitropropionic (3NP) acid in a rat model of Huntington's disease. We found that the occurrence of striatal lesions was accompanied by (1) strong transcriptional alterations within the degenerative lateral striatum, (2) receptor upregulations within the preserved medial striatum, and (3) transcriptional increases within the unaltered cerebral cortex. These phenomena were preceded by transcriptional modifications in striatal subareas prone to degeneration even before the lesion was visible but not in the overlying cortex, known to be spared in this model. Of great interest, the density of A(2A) receptor binding sites, located on striato-pallidal neurons, was (1) downregulated at the time of worsening of symptoms and (2) strongly upregulated within the spared medial striatum after the lesion occurrence. This study therefore highlights the differential neurochemical responses produced by 3NP depending on the fate of the metabolically inhibited area and strongly suggests the involvement of A(2A) receptors in the development of striatal pathology under metabolic compromise.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12270701     DOI: 10.1006/nbdi.2002.0512

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  7 in total

1.  Differential regulation of motor control and response to dopaminergic drugs by D1R and D2R neurons in distinct dorsal striatum subregions.

Authors:  Pierre F Durieux; Serge N Schiffmann; Alban de Kerchove d'Exaerde
Journal:  EMBO J       Date:  2011-11-08       Impact factor: 11.598

2.  Behavioral alterations in Lewis rats following two-day continuous 3-nitropropionic acid administration.

Authors:  J D Newcomb; W D Brown; A I Rodriguez; S Garbuzova-Davis; S Saporta; P R Sanberg; A E Willing
Journal:  Neurotox Res       Date:  2005-11       Impact factor: 3.911

3.  Decreased striatal dopamine release underlies increased expression of long-term synaptic potentiation at corticostriatal synapses 24 h after 3-nitropropionic-acid-induced chemical hypoxia.

Authors:  Garnik Akopian; Cynthia Crawford; M Flint Beal; Maurand Cappelletti; Michael W Jakowec; Giselle M Petzinger; Ling Zheng; Stacey L Gheorghe; Carmela M Reichel; Robert Chow; John P Walsh
Journal:  J Neurosci       Date:  2008-09-17       Impact factor: 6.167

4.  The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity.

Authors:  David Blum; David Gall; Marie-Christine Galas; Pablo d'Alcantara; Kadiombo Bantubungi; Serge N Schiffmann
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

Review 5.  Mouse models of Huntington's disease and methodological considerations for therapeutic trials.

Authors:  Robert J Ferrante
Journal:  Biochim Biophys Acta       Date:  2009-04-10

6.  Deletion of Maged1 in mice abolishes locomotor and reinforcing effects of cocaine.

Authors:  Jean-François De Backer; Stéphanie Monlezun; Bérangère Detraux; Adeline Gazan; Laura Vanopdenbosch; Julian Cheron; Giuseppe Cannazza; Sébastien Valverde; Lídia Cantacorps; Mérie Nassar; Laurent Venance; Olga Valverde; Philippe Faure; Michele Zoli; Olivier De Backer; David Gall; Serge N Schiffmann; Alban de Kerchove d'Exaerde
Journal:  EMBO Rep       Date:  2018-07-12       Impact factor: 8.807

7.  A role for oxidized DNA precursors in Huntington's disease-like striatal neurodegeneration.

Authors:  Gabriele De Luca; Maria Teresa Russo; Paolo Degan; Cecilia Tiveron; Andrea Zijno; Ettore Meccia; Ilenia Ventura; Elisabetta Mattei; Yusaku Nakabeppu; Marco Crescenzi; Rita Pepponi; Antonella Pèzzola; Patrizia Popoli; Margherita Bignami
Journal:  PLoS Genet       Date:  2008-11-21       Impact factor: 5.917

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.